At a glance
- What the study gets you
- Access to the study treatment being tested
- Type of study
- Interventional (receives a drug or procedure)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- Vipoglanstat (drug), Placebo (drug)
- How long the study runs
- Study runs about 20 months (dates as stated)
- About the drug or intervention
- Vipoglanstat — drug: Participants will receive vipoglanstat capsules orally for approximately 4 menstrual cycles during the treatment period. · Placebo — drug: Participants will receive matching placebo capsules orally for approximately 4 menstrual cycles during the treatment period.
- Patient visit burden
- Not specified by the sponsor
- Type of study
- Testing a treatment
- Ages
- 18 Years to 44 Years
- Who
- Female
- Number of participants
- 190
- Started
- 2025-10-15
- Last checked
- 2026-09
Plain English Summary
What is this study?
- • Testing a new treatment for endometriosis
- • Phase2 - 190 participants
- • The main objective of the trial is to evaluate the efficacy of vipoglanstat on endometriosis-related non-menstrual pelvic pain (NMPP)
Who can take part?
- • Ages 18 Years to 44 Years
- • Diagnosed with endometriosis
- • Female only
Where?
- • Bradford - Accellacare Yorkshire
- • Bristol - Southmead Hospital - North Bristol NHS Trust
- • Corby - Accellacare Northamptonshire
- • Coventry - Accellacare Warwickshire
- • +6 more UK sites
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
The main objective of the trial is to evaluate the efficacy of vipoglanstat on endometriosis-related non-menstrual pelvic pain (NMPP).
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: 18 Years - 44 Years
- Who can join: Female only
What the study is looking for
- ✓Premenopausal females 18 to \< 45 years of age at the time of Visit 1.
- ✓Endometriosis diagnosis confirmed and documented within the last 10 years prior to Visit 1 or during Visit based on:
- ✓Surgical (via direct visualization or biopsy verified) or
- ✓Imaging (ie, endometriotic lesion(s) detected by transvaginal sonography or magnetic resonance imaging \[MRI\].
- ✓History of NMPP significantly affecting daily life confirmed at Visit 1.
Who cannot take part
- ✗Has had more than 2 surgical procedures for endometriosis.
See the full criteria
Where Is This Study? (10 UK sites)
Accellacare Yorkshire
Bradford BD18 3SA, United Kingdom
Southmead Hospital - North Bristol NHS Trust
Bristol BS10 5NB, United Kingdom
Accellacare Northamptonshire
Corby NN18 9EZ, United Kingdom
Accellacare Warwickshire
Coventry CV3 4FJ, United Kingdom
Guy's and St Thomas' NHS Foundation Trust
London SE1 7EH, United Kingdom
Accellacare North London
Northwood HA6 2RN, United Kingdom
Norfolk and Norwich University Hospital - Norfolk and Norwich University Hospitals NHS Foundation Trust
Norwich NR4 7UY, United Kingdom
Accellacare South London
Orpington BR5 3QG, United Kingdom
University of Oxford
Oxford OX3 9DU, United Kingdom
Southampton General Hospital - University Hospital Southampton NHS Foundation Trust
Southampton SO16 6YD, United Kingdom
How to Get in Touch
CMO VP Clinical Development
Sponsor contactCONTACT
